Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Licenses Valentis GeneSwitch Technology

NEW YORK, August 1 – Lexicon Genetics has licensed Valentis' GeneSwitch gene regulation technology for use in its functional genomics research, the companies said on Wednesday.

Lexicon, based in The Woodlands, Texas, is the third company to license the technology from Valentis after GlaxoSmithKline and Wyeth-Ayerst Laboratories signed similar deals earlier this year. 

The non-exclusive license, which only covers research, involves an up-front payment to Valentis and annual maintenance fees.

Further financial details were not disclosed.

The GeneSwitch technology controls the expression of a gene in transgenic animals and cell cultures with a trigger that turns the expression of the gene on or off.

“Our evaluation of the GeneSwitch gene regulation technology indicates that it will allow Lexicon to more precisely control when and where specific genes are activated, adding another tool to our integrated technology platform for gene function and drug target discovery,” Mark Logan, manager of business development at Lexicon, said in a statement.

Valentis, based in Burlingame, Calif., holds all rights to clinical gene therapy applications of GeneSwitch and is currently applying the technology to a regulated erythropoietin gene therapeutic. Clinical testing of the erythropoietin medicine is expected to begin next year.

Valentis also makes the technology freely available to academic researchers through a collaboration with Invitrogen.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.